Your session is about to expire
← Back to Search
Acalabrutinib + Venetoclax + Durvalumab for Richter Syndrome
Study Summary
This trial tests acalabrutinib, venetoclax, and durvalumab in treating Richter transformation, a rare condition in which chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a fast-growing type of lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 177 Patients • NCT04346199Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I recently had a stem cell transplant or have chronic GVHD.I do not have uncontrolled heart problems.I have been diagnosed with CLL or SLL based on specific criteria.I have had cancer other than my current diagnosis.I have lung scarring or inflammation.I have a serious blood clotting disorder.My cancer has spread to my brain or spinal fluid.I regularly take medications that affect CYP3A.I have a long-term stomach or bowel condition that causes diarrhea.My CLL has transformed into a more aggressive form.I have been diagnosed with HIV, hepatitis B, or hepatitis C.I am 18 or older and agree to give consent and follow-up.I am not willing to use effective birth control methods.My liver tests for bilirubin, AST, and ALT are within required ranges.I do not have any ongoing serious infections or tuberculosis.I have recently had a live vaccine, radiation therapy, or major surgery.I am currently taking or have recently taken medication that weakens my immune system.I have an active autoimmune or inflammatory condition.My body weight is 30 kg or less.I have had progressive multifocal leukoencephalopathy in the past.I can take care of myself and am up and about more than half of my waking hours.I have not had a recent stroke or bleeding disorder.
- Group 1: Treatment (acalabrutinib, durvalumab, venetoclax)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial still recruiting participants?
"Yes, the data on clinicaltrials.gov suggests that this research endeavour is actively recruiting candidates. The study was first posted in 15th June 2022 and its most recent edit occurred on the same day. 33 individuals are required to be recruited from a single medical site."
Could you please elucidate the risks associated with taking Acalabrutinib?
"While there has been some evidence of safety, Acalabrutinib's efficacy is still undemonstrated. As such, our team at Power graded its risk level as a 2 on the 1-3 scale."
How many participants are partaking in this experiment at the most?
"Yes, indeed. The clinical trial is actively recruiting and the data hosted on clinicialtrials.gov suggests that recruitment began on June 15th 2022. 33 participants are needed at a single medical site for this study to be successful."
Share this study with friends
Copy Link
Messenger